AVEO Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVEO Pharmaceuticals

AVEO 15.00

0.0%

Jan 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	2/27/2013 10:07:27 PM
	Read Replies (1) of 8

Aveo Pharmaceuticals' NDA for tivozanib to be reviewed by FDA on May 2 AVEO and Astellas Pharma Global Development, a U.S. subsidiary of Tokyo-based Astellas Pharma, announced that the FDA's Oncologic Drugs Advisory Committee will review the company's New Drug Application for tivozanib for the treatment of patients with advanced renal cell carcinoma during the morning session of its meeting on May 2. ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer, and makes recommendations to the Commissioner of Food and Drugs. The review of the NDA is expected to be complete by July 28. Tivozanib is an investigational medicine and is not currently approved in any country.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next